Business
Quebec Pharmacists Launch ECG Screening for the Prevention of Drug Induced Sudden Cardiac Death
HeartCheck™ CardiBeat and SMART Monitoring ECG Triaging to be used in Screening Servi...
About this update from Cardiocomm Solutions, Inc.
[{"type":"text","content":"Quebec Pharmacists Launch ECG Screening for the Prevention of Drug Induced Sudden Cardiac DeathHeartCheck™ CardiBeat and SMART Monitoring ECG Triaging to be used in Screening Services for detection of QT Prolongation in Community PharmaciesTORONTO, ON / ACCESSWIRE / December 17, 2020 / CardioComm Solutions, Inc. (TSXV:EKG) (\"CardioComm\" or the \"Company\"), a global provider of consumer heart monitoring and electrocardiogram (\"ECG\") device and software solutions, confirms the start of a pharmacy-based ECG monitoring service to screen for prolonged QT interval for the prevention of drug induced sudden cardiac death.Under the Company's Allied Health Professional Partner Program, the HeartCheck™ CardiBeat and GEMS™ Mobile Smartphone app will be used to collect ECGs recorded by patients under the direction of a pharmacist. Recorded ECGs will be passed from the GEMS™ Mobile app to the Company's SMART Monitoring ECG reading service to be triaged. All findings will be sent directly to the pharmacist and any submitted ECG recordings that show a presence of prolonged QT interval or any other cardiac arrhythmia will be flagged so that the pharmacist may then follow up as needed with the patient's treating physician.Pharmacists plan to run ECG tests on patients when picking up a prescription. All QT and QTc interval findings will be kept on file with the goal of recording QT measurements for any patient with known cardiac issues and starting any new medication known to influence the QT interval. \"As polypharmacy analysis becomes more prevalent in a pharmacist's daily tasks, the use of the HeartCheck™ CardiBeat device will allow staff to quickly measure the patient's QT/QTc and make a clinical judgment as per the safety of the prescriptions being dispensed\", states pharmacist K. Manoukian.QT interval prolongation is a recognized adverse drug reaction and risk factor for torsades de pointes (TdP), a fatal arrhythmia that can result in sudden cardiac death. While rare, the severity of TdP makes QT prolongation a serious concern when prescribing medications.Pharmacists have a legal and professional responsibility to evaluate/mitigate medication adverse and serious adverse event risk factors and are the final decision makers in dispensing or not dispensing medications. The surface ECG is the only way to ...